Boston Scientific introduces Precision pain reliever
This article was originally published in The Gray Sheet
Executive Summary
Spinal cord stimulation system for the treatment of chronic pain in the limbs, trunk and back will undergo a full European launch in 2006, with initial roll-out to begin this year. The firm received a CE mark for the device Sept. 13. Boston Scientific acquired the PMA-approved device with its $740 mil. purchase of Advanced Bionics in June 2004 and launched it in the U.S. in March. The European version includes a longer-life battery - not yet approved in the U.S. - that can last up to 25 years. Boston Scientific is developing several additional indications for Precision, including migraine headache (1"The Gray Sheet" Feb. 7, 2005, p. 4)...
You may also be interested in...
Advanced Bionics Spinal Cord Stimulation Launch Continues With Precision
Boston Scientific's Advanced Bionics unit expects to have a 100-person sales force in place by the end of the third quarter to market its Precision spinal cord stimulation (SCS) system for chronic pain and future indications, including migraine headache
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.